Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,246 | 86 | 1,132 |
| Samples | 252 | 31 | 214 |
| Peptides | 231 | 21 | 219 |
Function
DCN · Decorin
This gene encodes a member of the small leucine-rich proteoglycan family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature protein. This protein plays a role in collagen fibril assembly. Binding of this protein to multiple cell surface receptors mediates its role in tumor suppression, including a stimulatory effect on autophagy and inflammation and an inhibitory effect on angiogenesis and tumorigenesis. This gene and the related gene biglycan are thought to be the result of a gene duplication. Mutations in this gene are associated with congenital stromal corneal dystrophy in human patients. [provided by RefSeq, Nov 2015].
Isoforms & Proteins
12 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000052754 | P07585 | 257 | 178 |
| ENST00000552962 | P07585 | 237 | 173 |
| ENST00000420120 | P07585-2 | 149 | 115 |
| ENST00000425043 | P07585-3 | 127 | 97 |
| ENST00000547568 | P07585-3 | 127 | 97 |
| ENST00000441303 | P07585-4 | 112 | 76 |
| ENST00000546745 | F8VU58* | 41 | 30 |
| ENST00000550099 | F8VU58* | 41 | 30 |
| ENST00000546370 | F8VNW0* | 40 | 29 |
| ENST00000551354 | F8VSI3* | 40 | 30 |
| ENST00000456569 | P07585-5 | 38 | 28 |
| ENST00000393155 | A0A7I2PRI8* | 37 | 27 |
Gene Properties
Recurrent Mutations
All 178 amino-acid changes on canonical ENST00000052754 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DCN · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DCN – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 19/612 3% |
| Melanoma | 1/210 0% | 53/1899 3% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 9/810 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 12/1390 1% |
| Colorectal Carcinoma | 6/143 4% | 26/3239 1% |
| Gastric Carcinoma | 1/74 1% | 16/1809 1% |
| Bladder Carcinoma | 1/58 2% | 7/956 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Hepatocellular Carcinoma | 0/46 0% | 13/2210 1% |
| Neuroendocrine Tumour | 2/154 1% | 2/577 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Other Solid Cancers | 1/94 1% | 6/1515 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 11/2550 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Kidney Carcinoma | 1/85 1% | 5/1862 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 3/2534 0% |
| Other Blood Cancers | 0/61 0% | 3/2725 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
Mutation Distribution
Where DCN is mutated · all tissues, split by cell line vs tissue
How many mutations in DCN were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,246 mutations in DCN
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|